Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Status:
Active, not recruiting
Trial end date:
2024-01-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the feasibility and evaluate the safety of
delivering chemoradiotherapy, the usual approach to non-small cell lung cancer, in
combination with pembrolizumab (MK-3745), followed by consolidation pembrolizumab after
surgical resection. Consolidation therapy is treatment given following the initial treatment.
Pembrolizumab is an investigational drug (also known as Keytruda), which has been approved by
the FDA for use in certain types of skin cancer (melanoma), and for use in certain types of
head and neck cancer. However, it has not been approved for use in other cancers such as
non-small cell lung cancer (NSCLC). Pembrolizumab is a monoclonal antibody that binds to the
surface of some cells of the immune system and activates them against cancer cells. It is not
chemotherapy.